Plasma Protein Therapeutics Market by Product (Albumin, Coagulation Factor, Hyperimmune Globulin), Indication (Cardiovascular, Neurological, Primary Immunodeficiency), Route Of Administration, End User - Global Forecast 2025-2032
Description
The Plasma Protein Therapeutics Market was valued at USD 28.87 billion in 2024 and is projected to grow to USD 30.38 billion in 2025, with a CAGR of 5.34%, reaching USD 43.78 billion by 2032.
A concise orientation to the plasma protein therapeutics landscape framing clinical dependence, manufacturing complexity, and policy pressures shaping industry strategy
Plasma protein therapeutics occupy a critical intersection of biotechnology, transfusion medicine, and clinical supply chain management, serving patients across immunodeficiency, coagulation disorders, trauma, and complex chronic conditions. Clinical reliance on fractionated plasma products and immunoglobulins remains strong because these biologics deliver established efficacy where synthetic alternatives are limited or unavailable. At the same time, advances in formulation science and delivery systems are reshaping clinical practice and patient experience, enabling more convenient subcutaneous alternatives and home-based administration in appropriate cases.
Operationally, the sector is characterized by complex upstream dependence on donor-sourced plasma, rigorous safety and traceability standards, and a manufacturing ecosystem that blends legacy fractionation techniques with cutting-edge recombinant and purification technologies. Policy changes, trade dynamics, and evolving reimbursement considerations are increasingly influential, prompting stakeholders to reassess supply security, sourcing strategies, and clinical pathways. This introduction frames the therapeutics landscape through the lenses of clinical need, manufacturing constraints, and policy pressures, establishing the baseline for the deeper analyses and recommendations that follow.
An analytical review of the strategic and technological shifts reshaping therapeutics development, supply chain resilience, and clinical delivery models in the sector
Recent years have seen a series of transformative shifts that are redefining how plasma protein therapeutics are developed, produced, and delivered. Technological innovation is accelerating formulation and delivery improvements, with greater emphasis on subcutaneous preparations and user-friendly dosing regimens that support home administration and reduce inpatient burden. Concurrently, supply chain modernization is gaining traction; companies are deploying enhanced traceability systems and cold-chain logistics solutions to protect product integrity across longer and more fragmented distribution networks.
Regulatory evolution and heightened safety expectations are also reshaping industry behavior. Authorities are tightening donor screening and testing protocols while encouraging transparency across the value chain, so manufacturers are investing in donor recruitment infrastructure and pathogen-reduction technologies. Commercial dynamics are changing as well: strategic consolidation and vertical integration have become common responses to margin pressure and supply variability, enabling some manufacturers to secure upstream access to plasma and improve cost predictability. Finally, patient-centric care models and payer-driven outcomes measures are nudging product development toward formulations that deliver better adherence and lower total cost of care. Together, these shifts are creating a market environment in which agility, traceability, and clinical differentiation determine competitive position.
A focused examination of how tariff changes in the United States reshaped sourcing strategies, investment priorities, and supplier relationships across the therapeutics value chain
The imposition of tariffs by the United States in 2025 introduced a new layer of operational and strategic complexity for organizations dependent on cross-border flows of plasma-derived products, raw materials, and manufacturing inputs. Immediate reactions from supply chain planners centered on rerouting shipments, renegotiating supplier terms, and reassessing contractual obligations to manage the direct cost impact and preserve continuity of care. Over time, procurement strategies adapted, with an increased emphasis on multi-sourcing, longer-term supplier relationships, and inventory buffers designed to mitigate episodic trade disruptions.
At the industrial level, tariffs created fresh incentives to accelerate investments in domestic collection capacity and localized processing capabilities, as stakeholders sought to reduce exposure to import tariffs and associated logistical risks. These investments often involved upgrading plasma collection centers and expanding regional fractionation capacity to capture greater value internally. Hospitals and clinics adjusted purchasing protocols, prioritizing suppliers with resilient distribution networks and clearer long-term commitments to product availability. The broader outcome has been a realignment of supplier-customer relationships, where transparency on origin, inventory depth, and supply continuity became prerequisites for selection. In parallel, manufacturers evaluated tariff-related cost increases against strategic benefits of onshoring critical operations, balancing near-term margin impacts with the potential for improved reliability and regulatory alignment.
Segment-level analysis revealing how product variants, therapeutic indications, administration routes, and care settings collectively determine clinical adoption and supply priorities
Segment-level dynamics clarify where clinical need, formulation innovation, and delivery models intersect to create differentiated opportunities across product, indication, route of administration, and end-user contexts. Product segmentation reflects a diverse portfolio that includes Albumin, Coagulation Factor, Hyperimmune Globulin, and Immunoglobulin. Albumin formulations, studied across Five Percent and Twenty Five Percent concentrations, remain central to critical care and volume management, favoring stability and established distribution networks. The Coagulation Factor category, differentiated into Factor IX, Factor VIII, and Prothrombin Complex Concentrate, is driven by advances in recombinant technologies, extended half-life formulations, and tailored dosing regimens that reduce infusion frequency. Hyperimmune Globulins studied for Hepatitis B, Rabies, Tetanus, and Varicella Zoster respond to episodic demand linked to public health events and travel medicine, requiring flexible manufacturing and rapid distribution capabilities. Immunoglobulin offerings, characterized by Intravenous Immunoglobulin and Subcutaneous Immunoglobulin formats, are evolving toward subcutaneous delivery to support home administration and improve patient quality of life.
Indication-based segmentation emphasizes therapeutic contexts such as Cardiovascular, Neurological, Primary Immunodeficiency, Secondary Immunodeficiency, and Trauma, each with distinct clinical protocols and reimbursement pathways that influence product selection and logistical priorities. Route of administration segmentation distinguishes Intramuscular, Intravenous, Oral, and Subcutaneous approaches, highlighting the trend toward minimally invasive and self-administered options that reduce hospital reliance. Finally, end-user segmentation between Clinics and Hospitals underscores divergent procurement cycles, storage capacities, and clinical workflows; clinics increasingly favor formulations and service models that enable outpatient management, while hospitals prioritize rapid access, bulk stocking, and integrated cold-chain solutions. Viewing these segments together reveals where clinical demand, convenience, and operational capability converge to favor specific formulations and distribution strategies.
A regional synthesis highlighting the distinct supply dynamics, regulatory challenges, and strategic priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific
Regional dynamics materially influence how products are manufactured, regulated, and delivered, creating distinct strategic priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust plasma collection infrastructure and established fractionation capacity underpin a mature supply base; this region continues to be a focal point for donor recruitment initiatives and technological upgrades in collection and testing. Policy actions and tariff settings in this region also strongly influence global trade flows and investment calculus for onshoring or expanding local capabilities.
The Europe, Middle East & Africa region presents a heterogeneous regulatory environment with pockets of high technical capacity and differing donor pool availability, requiring companies to adopt adaptive compliance frameworks and flexible logistics strategies. Cross-border trade within the region is common, but regulatory alignment and traceability demands necessitate careful coordination. In the Asia-Pacific region, accelerating demand driven by demographic and epidemiological shifts is outpacing domestic collection capacity in many markets, prompting strategic investments in local manufacturing, capacity partnerships, and public-private collaborations to expand plasma sourcing. Reimbursement structures and clinical practice patterns vary widely across these geographies, so commercial approaches must be tailored to local payer expectations and care delivery models. Taken together, regional insights emphasize the need for differentiated supply strategies, regulatory engagement plans, and partnerships that correspond to each region’s operational realities and growth drivers.
An industry-focused assessment of competitive strategies, vertical integration, and collaborative models that define leadership in the plasma protein therapeutics sector
Competitive dynamics in plasma protein therapeutics reflect a dual imperative: safeguarding reliable upstream plasma access while differentiating clinically via formulation, delivery, and service. Established manufacturers are investing in vertical integration to secure donor-sourced inputs and reduce exposure to trade volatility. At the same time, contract manufacturers and specialized technology providers play increasing roles in enabling capacity expansion and rapid response to episodic demand, particularly for hyperimmune products tied to public health events.
Companies are prioritizing portfolio diversification to include both traditional fractionated products and recombinant or purified alternatives that reduce dependence on donor plasma where clinically feasible. Strategic collaborations between manufacturers, healthcare providers, and logistics specialists are becoming more common, focused on improving end-to-end traceability, accelerating new product introductions, and expanding access to subcutaneous and home-delivered options. Investment in manufacturing automation, pathogen-reduction technologies, and data-driven supply planning also differentiates market leaders, who pair operational resilience with commercial agility to meet evolving clinical and policy expectations.
Clear, actionable directives for industry executives to strengthen supply resilience, accelerate patient-centric formulations, and align commercial models with payer expectations
Leaders in the field must pursue a set of targeted actions to navigate rising complexity while capturing clinical and commercial advantage. Strengthening plasma collection and donor engagement is foundational; this includes investment in modern collection centers, mobile donation units, and community outreach programs to broaden and stabilize donor pools. Parallel investments in manufacturing flexibility-such as modular production lines and contract capacity arrangements-reduce risk from episodic demand spikes and trade disruptions.
Supply chain resilience should be enhanced through diversified sourcing, strategic inventory positioning, and improved traceability systems that enable rapid response to recalls or regulatory inspections. Clinically, accelerating development and adoption of subcutaneous formulations and home-delivery models will address patient preferences and reduce healthcare resource utilization. On the commercial front, engaging payers and providers early to define value-based contracting models can align incentives and facilitate uptake of higher-value formulations. Finally, proactive regulatory engagement and scenario-based planning around trade policies and tariffs will help organizations anticipate disruptions and allocate capital to the most strategic opportunities. Executing these measures in concert will position organizations to deliver clinically meaningful therapies with greater reliability and operational efficiency.
A transparent description of the mixed-method research framework integrating primary interviews, secondary evidence synthesis, scenario analysis, and expert validation
The research approach combined qualitative and quantitative techniques to ensure a robust, multi-faceted understanding of the plasma protein therapeutics landscape. Primary inputs included structured interviews with clinicians, plasma center operators, manufacturing leaders, supply chain specialists, and payers to capture operational realities, clinical preferences, and procurement priorities. Secondary research drew on peer-reviewed clinical literature, regulatory guidance documents, manufacturing white papers, and industry reports to validate clinical trends, safety considerations, and technological advancements.
Analysis incorporated supply chain mapping, scenario planning around trade policy shifts, and segmentation analysis across product types, indications, routes of administration, and end-user contexts. Findings were triangulated via expert panels representing clinical, regulatory, and commercial perspectives to refine implications and test strategic recommendations. Limitations of the methodology include the evolving nature of trade policies and clinical trial outcomes, which require periodic reassessment, and variability in donor availability that can create short-term deviations from longer-term trends. Nonetheless, the combined methodological approach supports a nuanced, actionable view of industry dynamics.
A concise synthesis capturing the strategic imperatives and opportunity levers that will determine long-term resilience and competitive advantage in the sector
The collective analysis underscores that plasma protein therapeutics remain indispensable to modern clinical practice, yet the sector is navigating significant operational, regulatory, and commercial changes that require deliberate strategic responses. Technological advances in formulation and delivery are enabling more patient-centric care pathways, while supply chain and policy dynamics are reshaping where and how products are produced and distributed. Organizations that proactively secure upstream access to plasma, invest in manufacturing and distribution resilience, and align product development with payer and provider needs will be best positioned to sustain delivery of critical therapies.
In closing, the most compelling opportunities arise where clinical differentiation meets operational reliability: formulations that improve adherence and enable outpatient care, paired with supply chains capable of dependable performance under stress. Strategic clarity, coupled with disciplined execution in donor engagement, manufacturing flexibility, and regulatory collaboration, will determine which organizations convert today’s challenges into long-term competitive advantage.
Please Note: PDF & Excel + Online Access - 1 Year
A concise orientation to the plasma protein therapeutics landscape framing clinical dependence, manufacturing complexity, and policy pressures shaping industry strategy
Plasma protein therapeutics occupy a critical intersection of biotechnology, transfusion medicine, and clinical supply chain management, serving patients across immunodeficiency, coagulation disorders, trauma, and complex chronic conditions. Clinical reliance on fractionated plasma products and immunoglobulins remains strong because these biologics deliver established efficacy where synthetic alternatives are limited or unavailable. At the same time, advances in formulation science and delivery systems are reshaping clinical practice and patient experience, enabling more convenient subcutaneous alternatives and home-based administration in appropriate cases.
Operationally, the sector is characterized by complex upstream dependence on donor-sourced plasma, rigorous safety and traceability standards, and a manufacturing ecosystem that blends legacy fractionation techniques with cutting-edge recombinant and purification technologies. Policy changes, trade dynamics, and evolving reimbursement considerations are increasingly influential, prompting stakeholders to reassess supply security, sourcing strategies, and clinical pathways. This introduction frames the therapeutics landscape through the lenses of clinical need, manufacturing constraints, and policy pressures, establishing the baseline for the deeper analyses and recommendations that follow.
An analytical review of the strategic and technological shifts reshaping therapeutics development, supply chain resilience, and clinical delivery models in the sector
Recent years have seen a series of transformative shifts that are redefining how plasma protein therapeutics are developed, produced, and delivered. Technological innovation is accelerating formulation and delivery improvements, with greater emphasis on subcutaneous preparations and user-friendly dosing regimens that support home administration and reduce inpatient burden. Concurrently, supply chain modernization is gaining traction; companies are deploying enhanced traceability systems and cold-chain logistics solutions to protect product integrity across longer and more fragmented distribution networks.
Regulatory evolution and heightened safety expectations are also reshaping industry behavior. Authorities are tightening donor screening and testing protocols while encouraging transparency across the value chain, so manufacturers are investing in donor recruitment infrastructure and pathogen-reduction technologies. Commercial dynamics are changing as well: strategic consolidation and vertical integration have become common responses to margin pressure and supply variability, enabling some manufacturers to secure upstream access to plasma and improve cost predictability. Finally, patient-centric care models and payer-driven outcomes measures are nudging product development toward formulations that deliver better adherence and lower total cost of care. Together, these shifts are creating a market environment in which agility, traceability, and clinical differentiation determine competitive position.
A focused examination of how tariff changes in the United States reshaped sourcing strategies, investment priorities, and supplier relationships across the therapeutics value chain
The imposition of tariffs by the United States in 2025 introduced a new layer of operational and strategic complexity for organizations dependent on cross-border flows of plasma-derived products, raw materials, and manufacturing inputs. Immediate reactions from supply chain planners centered on rerouting shipments, renegotiating supplier terms, and reassessing contractual obligations to manage the direct cost impact and preserve continuity of care. Over time, procurement strategies adapted, with an increased emphasis on multi-sourcing, longer-term supplier relationships, and inventory buffers designed to mitigate episodic trade disruptions.
At the industrial level, tariffs created fresh incentives to accelerate investments in domestic collection capacity and localized processing capabilities, as stakeholders sought to reduce exposure to import tariffs and associated logistical risks. These investments often involved upgrading plasma collection centers and expanding regional fractionation capacity to capture greater value internally. Hospitals and clinics adjusted purchasing protocols, prioritizing suppliers with resilient distribution networks and clearer long-term commitments to product availability. The broader outcome has been a realignment of supplier-customer relationships, where transparency on origin, inventory depth, and supply continuity became prerequisites for selection. In parallel, manufacturers evaluated tariff-related cost increases against strategic benefits of onshoring critical operations, balancing near-term margin impacts with the potential for improved reliability and regulatory alignment.
Segment-level analysis revealing how product variants, therapeutic indications, administration routes, and care settings collectively determine clinical adoption and supply priorities
Segment-level dynamics clarify where clinical need, formulation innovation, and delivery models intersect to create differentiated opportunities across product, indication, route of administration, and end-user contexts. Product segmentation reflects a diverse portfolio that includes Albumin, Coagulation Factor, Hyperimmune Globulin, and Immunoglobulin. Albumin formulations, studied across Five Percent and Twenty Five Percent concentrations, remain central to critical care and volume management, favoring stability and established distribution networks. The Coagulation Factor category, differentiated into Factor IX, Factor VIII, and Prothrombin Complex Concentrate, is driven by advances in recombinant technologies, extended half-life formulations, and tailored dosing regimens that reduce infusion frequency. Hyperimmune Globulins studied for Hepatitis B, Rabies, Tetanus, and Varicella Zoster respond to episodic demand linked to public health events and travel medicine, requiring flexible manufacturing and rapid distribution capabilities. Immunoglobulin offerings, characterized by Intravenous Immunoglobulin and Subcutaneous Immunoglobulin formats, are evolving toward subcutaneous delivery to support home administration and improve patient quality of life.
Indication-based segmentation emphasizes therapeutic contexts such as Cardiovascular, Neurological, Primary Immunodeficiency, Secondary Immunodeficiency, and Trauma, each with distinct clinical protocols and reimbursement pathways that influence product selection and logistical priorities. Route of administration segmentation distinguishes Intramuscular, Intravenous, Oral, and Subcutaneous approaches, highlighting the trend toward minimally invasive and self-administered options that reduce hospital reliance. Finally, end-user segmentation between Clinics and Hospitals underscores divergent procurement cycles, storage capacities, and clinical workflows; clinics increasingly favor formulations and service models that enable outpatient management, while hospitals prioritize rapid access, bulk stocking, and integrated cold-chain solutions. Viewing these segments together reveals where clinical demand, convenience, and operational capability converge to favor specific formulations and distribution strategies.
A regional synthesis highlighting the distinct supply dynamics, regulatory challenges, and strategic priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific
Regional dynamics materially influence how products are manufactured, regulated, and delivered, creating distinct strategic priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust plasma collection infrastructure and established fractionation capacity underpin a mature supply base; this region continues to be a focal point for donor recruitment initiatives and technological upgrades in collection and testing. Policy actions and tariff settings in this region also strongly influence global trade flows and investment calculus for onshoring or expanding local capabilities.
The Europe, Middle East & Africa region presents a heterogeneous regulatory environment with pockets of high technical capacity and differing donor pool availability, requiring companies to adopt adaptive compliance frameworks and flexible logistics strategies. Cross-border trade within the region is common, but regulatory alignment and traceability demands necessitate careful coordination. In the Asia-Pacific region, accelerating demand driven by demographic and epidemiological shifts is outpacing domestic collection capacity in many markets, prompting strategic investments in local manufacturing, capacity partnerships, and public-private collaborations to expand plasma sourcing. Reimbursement structures and clinical practice patterns vary widely across these geographies, so commercial approaches must be tailored to local payer expectations and care delivery models. Taken together, regional insights emphasize the need for differentiated supply strategies, regulatory engagement plans, and partnerships that correspond to each region’s operational realities and growth drivers.
An industry-focused assessment of competitive strategies, vertical integration, and collaborative models that define leadership in the plasma protein therapeutics sector
Competitive dynamics in plasma protein therapeutics reflect a dual imperative: safeguarding reliable upstream plasma access while differentiating clinically via formulation, delivery, and service. Established manufacturers are investing in vertical integration to secure donor-sourced inputs and reduce exposure to trade volatility. At the same time, contract manufacturers and specialized technology providers play increasing roles in enabling capacity expansion and rapid response to episodic demand, particularly for hyperimmune products tied to public health events.
Companies are prioritizing portfolio diversification to include both traditional fractionated products and recombinant or purified alternatives that reduce dependence on donor plasma where clinically feasible. Strategic collaborations between manufacturers, healthcare providers, and logistics specialists are becoming more common, focused on improving end-to-end traceability, accelerating new product introductions, and expanding access to subcutaneous and home-delivered options. Investment in manufacturing automation, pathogen-reduction technologies, and data-driven supply planning also differentiates market leaders, who pair operational resilience with commercial agility to meet evolving clinical and policy expectations.
Clear, actionable directives for industry executives to strengthen supply resilience, accelerate patient-centric formulations, and align commercial models with payer expectations
Leaders in the field must pursue a set of targeted actions to navigate rising complexity while capturing clinical and commercial advantage. Strengthening plasma collection and donor engagement is foundational; this includes investment in modern collection centers, mobile donation units, and community outreach programs to broaden and stabilize donor pools. Parallel investments in manufacturing flexibility-such as modular production lines and contract capacity arrangements-reduce risk from episodic demand spikes and trade disruptions.
Supply chain resilience should be enhanced through diversified sourcing, strategic inventory positioning, and improved traceability systems that enable rapid response to recalls or regulatory inspections. Clinically, accelerating development and adoption of subcutaneous formulations and home-delivery models will address patient preferences and reduce healthcare resource utilization. On the commercial front, engaging payers and providers early to define value-based contracting models can align incentives and facilitate uptake of higher-value formulations. Finally, proactive regulatory engagement and scenario-based planning around trade policies and tariffs will help organizations anticipate disruptions and allocate capital to the most strategic opportunities. Executing these measures in concert will position organizations to deliver clinically meaningful therapies with greater reliability and operational efficiency.
A transparent description of the mixed-method research framework integrating primary interviews, secondary evidence synthesis, scenario analysis, and expert validation
The research approach combined qualitative and quantitative techniques to ensure a robust, multi-faceted understanding of the plasma protein therapeutics landscape. Primary inputs included structured interviews with clinicians, plasma center operators, manufacturing leaders, supply chain specialists, and payers to capture operational realities, clinical preferences, and procurement priorities. Secondary research drew on peer-reviewed clinical literature, regulatory guidance documents, manufacturing white papers, and industry reports to validate clinical trends, safety considerations, and technological advancements.
Analysis incorporated supply chain mapping, scenario planning around trade policy shifts, and segmentation analysis across product types, indications, routes of administration, and end-user contexts. Findings were triangulated via expert panels representing clinical, regulatory, and commercial perspectives to refine implications and test strategic recommendations. Limitations of the methodology include the evolving nature of trade policies and clinical trial outcomes, which require periodic reassessment, and variability in donor availability that can create short-term deviations from longer-term trends. Nonetheless, the combined methodological approach supports a nuanced, actionable view of industry dynamics.
A concise synthesis capturing the strategic imperatives and opportunity levers that will determine long-term resilience and competitive advantage in the sector
The collective analysis underscores that plasma protein therapeutics remain indispensable to modern clinical practice, yet the sector is navigating significant operational, regulatory, and commercial changes that require deliberate strategic responses. Technological advances in formulation and delivery are enabling more patient-centric care pathways, while supply chain and policy dynamics are reshaping where and how products are produced and distributed. Organizations that proactively secure upstream access to plasma, invest in manufacturing and distribution resilience, and align product development with payer and provider needs will be best positioned to sustain delivery of critical therapies.
In closing, the most compelling opportunities arise where clinical differentiation meets operational reliability: formulations that improve adherence and enable outpatient care, paired with supply chains capable of dependable performance under stress. Strategic clarity, coupled with disciplined execution in donor engagement, manufacturing flexibility, and regulatory collaboration, will determine which organizations convert today’s challenges into long-term competitive advantage.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
194 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Advances in recombinant plasma protein manufacturing reducing reliance on donor plasma supply
- 5.2. Increasing adoption of subcutaneous immunoglobulin therapies for primary immunodeficiency patients
- 5.3. Implementation of novel viral inactivation techniques enhancing safety of fractionated plasma products
- 5.4. Rising demand for alpha-1 antitrypsin augmentation therapy driven by better diagnostic screening
- 5.5. Strategic collaborations between biopharma and plasma collection centers to expand hyperimmune globulin portfolios
- 5.6. Regulatory approvals for next-generation coagulation factors improving treatment options for hemophilia
- 5.7. Emergence of cell-based expression platforms for monoclonal immunoglobulin production reducing costs
- 5.8. Supply chain digitalization and cold chain optimization ensuring uninterrupted immunoglobulin availability
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Plasma Protein Therapeutics Market, by Product
- 8.1. Albumin
- 8.1.1. Five Percent
- 8.1.2. Twenty Five Percent
- 8.2. Coagulation Factor
- 8.2.1. Factor IX
- 8.2.2. Factor VIII
- 8.2.3. Prothrombin Complex Concentrate
- 8.3. Hyperimmune Globulin
- 8.3.1. Hepatitis B
- 8.3.2. Rabies
- 8.3.3. Tetanus
- 8.3.4. Varicella Zoster
- 8.4. Immunoglobulin
- 8.4.1. Intravenous Immunoglobulin
- 8.4.2. Subcutaneous Immunoglobulin
- 9. Plasma Protein Therapeutics Market, by Indication
- 9.1. Cardiovascular
- 9.2. Neurological
- 9.3. Primary Immunodeficiency
- 9.4. Secondary Immunodeficiency
- 9.5. Trauma
- 10. Plasma Protein Therapeutics Market, by Route Of Administration
- 10.1. Intramuscular
- 10.2. Intravenous
- 10.3. Oral
- 10.4. Subcutaneous
- 11. Plasma Protein Therapeutics Market, by End User
- 11.1. Clinics
- 11.2. Hospitals
- 12. Plasma Protein Therapeutics Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Plasma Protein Therapeutics Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Plasma Protein Therapeutics Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. CSL Behring
- 15.3.2. Takeda Pharmaceutical Company Limited
- 15.3.3. Grifols, S.A.
- 15.3.4. Octapharma AG
- 15.3.5. Kedrion Biopharma
- 15.3.6. Biotest AG
- 15.3.7. China Biologic Products Holdings, Inc.
- 15.3.8. GC Pharma
- 15.3.9. Bio Products Laboratory Ltd
- 15.3.10. ADMA Biologics, Inc.
- 15.3.11. Kamada Ltd.
- 15.3.12. LFB S.A.
- 15.3.13. Sanquin Plasma Products B.V.
- 15.3.14. Hualan Biological Engineering Inc.
- 15.3.15. Baxter International, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
